2025 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Collaborations between large pharma companies and digital therapeutics firms have been growing in the last few years. Otsuka and Click’s Rejoyn is the latest step forward.
Japan has announced several new measures to tackle the lack of rare disease and other therapeutics in the domestic market, with the country's main industry association also issuing the first common national informed consent form in a bid to lighten the “huge workload” on trial site staff.
Through a new full-time office in the US capital, Japan's drug regulator aims to provide essential regulatory information to help US bioventures enter the Japanese market at an early stage.
